Allspring Global Investments Holdings, LLC Fate Therapeutics Inc Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	BUY	$1.65 - $3.94 $7,197 - $17,186	4,362 New	4,362 $16,000
Q2 2023 Jul 18, 2023	BUY	$4.76 - $6.59 $8,134 - $11,262	1,709 Added 105.95%	3,322 $15,000
Q1 2023 Apr 13, 2023	SELL	$4.24 - $11.12 $163,015 - $427,530	-38,447 Reduced 95.97%	1,613 $9,000
Q4 2022 Jan 23, 2023	SELL	$9.86 - $23.83 $2.06 Million - $4.97 Million	-208,559 Reduced 83.89%	40,060 $0
Q3 2022 Oct 26, 2022	BUY	$21.04 - $36.06 $637,869 - $1.09 Million	30,317 Added 13.89%	248,619 $5.57 Million
Q2 2022 Jul 25, 2022	SELL	$17.78 - $42.39 $391,604 - $933,639	-22,025 Reduced 9.16%	218,302 $5.41 Million
Q1 2022 May 02, 2022	SELL	$29.67 - $60.28 $104,438 - $212,185	-3,520 Reduced 1.44%	240,327 $9.32 Million
Q4 2021 Jan 28, 2022	BUY	$47.84 - $64.34 $11.7 Million - $15.7 Million	243,847 New	243,847 $14.3 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account